ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable ...

Small fiber neuropathy (SFN) is a chronic and debilitating condition caused by damage to peripheral sensory nerves, which are responsible for pain, temperature sensation and autonomic functions.

January 8, 2026 – National Institutes of Health (NIH) released the following: ...

Beyond sicca symptoms, Sjögren's disease can involve non-glandular manifestations such as dysautonomia and small fiber neuropathy that are often difficult to assess and manage. At this year's American ...

Coral Gables, Fla.-based Baptist Health’s Miami Neuroscience Institute has added Adriana Arenas, MD, as a nonsurgical spine care physician, effective Jan. 6. Dr. Arenas specializes in physical ...

The last time I spoke about Sangamo Therapeutics, Inc. (SGMO) it was regarding a Seeking Alpha article entitled “Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory ...

Sangamo Therapeutics Inc. has received IND clearance from the FDA for ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy ...

A research team supported by the National Institutes of Health (NIH) has found that conditions known to cause nerve damage, ...

A $3.6 million award from the National Institutes of Health will allow neurosurgical, neurology and neuroscience researchers at The Ohio State University Wexner Medical Center and College of Medicine ...